india top court to deliver key drug patent ruling
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice
Emiratesvoice, emirates voice
Last Updated : GMT 05:17:37
Emiratesvoice, emirates voice

India top court to deliver key drug patent ruling

Emiratesvoice, emirates voice

Emiratesvoice, emirates voice India top court to deliver key drug patent ruling

New Delhi - AFP

India\'s Supreme Court is set to rule Monday on a patent challenge by Swiss drug giant Novartis that activists say threatens access to cheap generic versions of life-saving drugs in developing nations. The landmark case -- watched closely by global drug firms and patient groups -- involves an updated version of Novartis\' blockbuster cancer drug Glivec, for which the company has fought a seven-year legal battle to win patent protection. India\'s patent office has so far refused to grant protection, asserting that the amended form of Glivec was not vastly different from the earlier version. The challenge strikes at the heart of India\'s patent law, which restricts pharmaceutical companies from seeking fresh patents for making only small modifications to existing drugs -- an industry practice known as \"evergreening\". The case is the most high-profile of several patent battles being waged in India and could have far-reaching implications in defining the extent of patent protection for multinational drug firms operating in the lucrative market. The Swiss firm has threatened to halt supplies of new medicines to India if the court does not rule in its favour, London\'s Financial Times reported on Sunday. \"If the situation stays as now, all improvements on an original compound are not protectable and such drugs would probably not be rolled out in India,\" said executive Paul Herrling, who is leading the company\'s handling of the case. \"Why would we?\" he was quoted as saying by the newspaper. But Leena Menghaney, a lawyer with medical charity Medecins Sans Frontieres (MSF), says a legal victory for Novartis could \"set a dangerous precedent, severely weakening India\'s legal norms against evergreening\". It would \"be dire for people in the developing world who depend on generic drugs made in this country. It could seriously curb access\". Generic drug firms in India -- long known as the \"pharmacy to the developing world\" -- have been a major supplier of copycat medicines to treat diseases such as cancer, TB and AIDS for those who cannot afford expensive branded versions. The cost difference between generic and branded drugs is crucial for poor people around the world, MSF says. It points out that Glivec -- often hailed as a \"silver bullet\" for its breakthrough in treating a deadly form of leukaemia -- costs $4,000 a month in its branded form while its generic version is available in India for around $73. But Novartis and other global drugmakers say India\'s generics industry inhibits pharmaceutical innovation and reduces commercial incentives to produce cutting-edge medicines. The verdict is keenly awaited by many global drug firms hoping to sell branded medicines in the nation of 1.2 billion people where the pharmaceutical market is set to touch $74 billion in sales by 2020 from $11 billion in 2011. India\'s copycat drugs industry, which supplies one-fifth of the world\'s generics, grew into a powerhouse because the country did not issue drug patents until 2005 when it began complying with World Trade Organisation rules. India currently allows patents only for new drugs or for an updated version of a drug that displays \"enhanced\" therapeutic efficiency.  

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

india top court to deliver key drug patent ruling india top court to deliver key drug patent ruling

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

india top court to deliver key drug patent ruling india top court to deliver key drug patent ruling

 



GMT 10:31 2014 Tuesday ,23 December

Mirages of failure: Lebanon cannot wait

GMT 10:08 2018 Wednesday ,24 January

Microsoft to open 4 data centres

GMT 21:41 2017 Tuesday ,31 October

Deaths, numerous injuries in New York crash

GMT 11:49 2016 Monday ,14 March

Palestinian wins $1m global teaching prize

GMT 07:57 2017 Monday ,04 December

Women take lead at contemporary dance festival

GMT 10:17 2011 Friday ,30 September

Yemeni star Arwa would not perform for free

GMT 09:27 2017 Thursday ,20 July

Dubai Municipality closes 94 food outlets

GMT 11:11 2017 Tuesday ,14 November

HRH Premier's patronage of Invest-in-Bahrain hailed

GMT 10:00 2017 Saturday ,11 February

No room for sentiment as Six Nations take shape

GMT 14:16 2017 Thursday ,13 July

Kittel maintains Tour sprint domination

GMT 09:52 2018 Wednesday ,17 January

Pretty dresses are no longer just

GMT 13:10 2018 Thursday ,11 January

Uproar in Hollywood over Williams-Wahlberg pay
 
 Emirates Voice Facebook,emirates voice facebook  Emirates Voice Twitter,emirates voice twitter Emirates Voice Rss,emirates voice rss  Emirates Voice Youtube,emirates voice youtube  Emirates Voice Youtube,emirates voice youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

emiratesvoieen emiratesvoiceen emiratesvoiceen emiratesvoiceen
emiratesvoice emiratesvoice emiratesvoice
emiratesvoice
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
emiratesvoice, Emiratesvoice, Emiratesvoice